103 related articles for article (PubMed ID: 21853932)
1. [The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome].
Banaszewska B; Spaczyński RZ; Ozegowska K; Pawelczyk L
Ginekol Pol; 2011 Jun; 82(6):430-5. PubMed ID: 21853932
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial.
Banaszewska B; Pawelczyk L; Spaczynski RZ; Dziura J; Duleba AJ
J Clin Endocrinol Metab; 2007 Feb; 92(2):456-61. PubMed ID: 17105841
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
Adeniji AA; Essah PA; Nestler JE; Cheang KI
J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
6. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
Gode F; Karagoz C; Posaci C; Saatli B; Uysal D; Secil M; Akdeniz B
Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination.
Bahceci M; Bilge M; Tuzcu A; Tuzcu S; Bahceci S
J Endocrinol Invest; 2004 Apr; 27(4):353-6. PubMed ID: 15233555
[TBL] [Abstract][Full Text] [Related]
8. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Glintborg D; Altinok ML; Mumm H; Hermann AP; Ravn P; Andersen M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2584-91. PubMed ID: 24742124
[TBL] [Abstract][Full Text] [Related]
9. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
10. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
[TBL] [Abstract][Full Text] [Related]
11. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
Minozzi M; Costantino D; Guaraldi C; Unfer V
Gynecol Endocrinol; 2011 Nov; 27(11):920-4. PubMed ID: 21417594
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
Yildizhan R; Gokce AI; Yildizhan B; Cim N
Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome.
Bhattacharya SM; Jha A; DasMukhopadhyay L
Int J Gynaecol Obstet; 2016 Feb; 132(2):210-3. PubMed ID: 26613823
[TBL] [Abstract][Full Text] [Related]
15. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
16. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
Bhattacharya SM; Ghosh M; Basu R
J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
19. Effects of a monophasic pill containing 20 microg ethinylestradiol and 150 microg desogestrel on lipid metabolism in Thai women.
Jaisamrarn U; Taneepanichskul S; Wongwathanavikromn R; Reinprayoon D
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S429-34. PubMed ID: 12188447
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
Akerlund M
Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]